13 results about "Embolization Agent" patented technology

The invention belongs to the technical field of medical instruments. In order to solve the problem that an existing device is tedious in operation, the multifunctional automatic injection system is designed and comprises an injector, an automatic injection device and an auxiliary Y valve, and the auxiliary Y valve is connected with a catheter, a guide wire and the automatic injection device. Therefore, the automatic injection device can inject the contrast agent, the medicine or the embolic agent in the injector, the contrast or treatment efficiency is improved, meanwhile, the guide wire can be rapidly fixed, the guide wire does not need to be completely withdrawn out of the catheter, the surgical operation difficulty is reduced, and the surgical time is shortened.

The application discloses a master-slave separated embolism agent mixed injection device, which solves the liquid layering phenomenon in the operation process, and comprises an execution end arranged in an operating room and a control end arranged in a control room and capable of controlling the execution end. The control end comprises an embedded controller, a signal collector and an injection handle, the control end and the execution end are in wireless communication, the execution end comprises a drug carrying module, a shaking module and an injection module; the drug carrying module is used for carrying a needle cylinder carrying a drug; the injection module is used for pushing the needle cylinder on the drug carrying module in an injection direction to perform injection; and the shaking module is used for reciprocating the needle cylinder in the drug carrying module in a direction perpendicular to the injection direction. In the application, the shaking module realizes reciprocating operation by cooperation of a rack and a non-complete gear, the needle cylinder can realize small-range shaking in a horizontal plane, and finally the purpose of mixing the drug liquid is achieved, which is close to the artificial mixing process.

An embolic hydrogel for a patient comprises an aqueous buffer and at least one functionalized polymer, each having at least one polymer backbone chemically modified with one or more functional groups. The functional groups facilitate the formation of a primary reversible cross-link on the polymer backbone such that the embolic hydrogel transitions from a gel state to a viscous liquid state in response to shear forces applied to the embolic hydrogel and transitions from the viscous liquid state to the gel state in response to the absence of shear forces applied to the embolic hydrogel. The embolic hydrogel also includes at least one phase change polymer that produces secondary crosslinking therein in response to a physiological environment such that the embolic hydrogel transitions from a gel state to a solid state.

The invention discloses a natural polymer polyelectrolyte microsphere as well as a preparation method and application thereof, the microsphere is of a covalent and non-covalent double-crosslinking network structure formed by crosslinking natural polymer and polyelectrolyte, and the modification degree of the crosslinked natural polymer is 1.0-50.0%; the natural polymer is a compound containing more than two carboxyl groups or amino groups or a combination of the carboxyl groups and the amino groups; and the polyelectrolyte is a compound containing more than two carboxyl groups or amino groups or a combination of the carboxyl groups and the amino groups. The preparation method comprises the following steps: S1, dissolving a natural polymer and a polyelectrolyte in a water phase to generate an electrostatic complex; s2, adding enzyme into the electrostatic complex and incubating to form microspheres; and S3, adding a condensing agent and / or a cross-linking agent, removing the unreacted condensing agent and / or cross-linking agent, and sterilizing to obtain the natural polymer polyelectrolyte microspheres. The microsphere can be used as an embolism agent in an interventional technology or a separation and purification medium of protein, antibodies and drugs or a cell and drug carrier system, or as an implant material for orthopedics, surgery, ophthalmology and medical beauty.

The invention discloses a balloon micro-catheter and belongs to the technical field of medical instruments. The balloon micro-catheter comprises a catheter body and a balloon. The tube body has a proximal end and a distal end in an axial direction thereof. The pipe body comprises an inner pipe and an outer pipe arranged outside the inner pipe in a sleeving mode, and a gap between the inner pipe and the outer pipe forms a filling cavity. A control cavity extending in the axial direction is formed in the tube wall of the outer tube, a control wire is arranged in the control cavity in a penetrating mode, the far end of the control wire is connected with the far end of the outer tube, and the near end of the control wire penetrates out of the control cavity. A first pin of the balloon is connected with the far end of the outer tube, and a second pin of the balloon is connected with the far end of the inner tube, so that the filling cavity is communicated with the balloon. When the balloon micro-catheter is used, the inner tube and the outer tube can be bent through the control wire, liquid is filled into the balloon through the filling cavity to enable the balloon to be filled and expanded, an embolism agent or an instrument is conveyed through the infusion cavity of the inner tube, and the balloon micro-catheter and an embolism micro-catheter which are independent do not need to penetrate into the balloon micro-catheter and the embolism micro-catheter respectively. The catheter operation process can be simplified, and the treatment safety can be improved.

The invention relates to the technical field of nano preparations, in particular to a temperature-sensitive liposome embolization agent as well as a preparation method and application thereof. The temperature-sensitive lipidosome embolization agent comprises lipidosome and a temperature-sensitive polymer modified on the surface of the lipidosome, the temperature-sensitive polymer can be crosslinked under the triggering of body temperature, so that the temperature-sensitive liposome embolization agent is converted into hydrogel with a three-dimensional network structure from a sol state. According to the invention, the surface of the liposome is modified by adopting the temperature-sensitive polymer instead of DSPE-PEG in the traditional liposome, so that the liposome is endowed with excellent temperature-sensitive response characteristic. The temperature-sensitive polymer can be subjected to hydrophilic and hydrophobic transformation and cross-linking under the condition of body temperature, so that the liposome embolism agent is subjected to sol-gel transformation at a blood vessel part, and controllable triggering and enhancement of the embolism process are realized.

The invention discloses application of a chemotherapy drug-microalgae embolization agent in preparation of a drug for treating tumors through arterial embolization, belongs to the technical field of biological medicine, and particularly relates to the technical field of biological medicine manufacturing, and the chemotherapy drug-microalgae embolization agent is composed of a pharmacologically effective amount of chemotherapy drug and microalgae, the chemotherapeutic drug is electropositive in a physiological environment and is combined with the microalgae through electrostatic adsorption, and preferably, the mass ratio of the microalgae to the chemotherapeutic drug is 1: (0.1-10). The chemotherapy drug-microalgae embolization agent has pH responsiveness when releasing chemotherapy drugs, and can improve an acidic tumor microenvironment, so that the antitumor effect is synergistically enhanced; the chemotherapeutic drug, namely the microalgae embolization agent, also has good biocompatibility and biodegradability. The chemotherapeutic drug-loaded microalgae provided by the invention provides clinical transformation potential for malignant tumor treatment.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

The invention discloses a pharmaceutical composition for tumor embolism treatment. The pharmaceutical composition consists of a tirapazamine derivative RTPZ and iodophol. The preparation method comprises the following steps: S1, dissolving tirapazamine and an alkaline substance in a solvent, and adding alkyl acyl chloride for reaction until the raw materials are completely converted; s2, after the reaction in the S1 is finished, performing rotary evaporation to remove the solvent, adding dichloromethane for dissolving, washing with a saturated saline solution, drying with anhydrous sodium sulfate, and finally evaporating to remove the solvent to obtain a crude product; s3, purifying the crude product to obtain RTPZ; and S4, directly dissolving the RTPZ in the iodinated oil until the RTPZ is saturated. According to the invention, the characteristics of a high oil-soluble drug, an iodized oil embolism agent and slow release are integrated, a local, slow-release and target hypoxic tumor treatment system for transcatheter arterial chemoembolization is constructed, an anti-tumor effect far better than that of a raw drug TPZ is achieved on a VX2 rabbit tumor embolism model, and a microenvironment after embolism can be effectively regulated and controlled.

The invention discloses a shear thinning hydrogel embolization agent based on temperature-sensitive enhancement and a preparation method thereof, and belongs to the technical field of medical polymer materials. Quaternized magnesium lithium silicate is grafted to carboxymethyl chitosan through ionic bonds, the shear thinning performance of the magnesium lithium silicate can be enhanced by adjusting the grafting rate, the catheter conveying performance of the hydrogel is improved, meanwhile, beta-glycerophosphate is added to form a temperature-sensitive system with the modified carboxymethyl chitosan, gel is spontaneously formed in vivo at 33-37 DEG C, and the hydrogel is used for preparing a temperature-sensitive hydrogel. The embolism strength is further enhanced, and any initiator does not need to be added. The shear thinning characteristic of the inorganic nanosheet and the polysaccharide temperature-sensitive gel characteristic are combined, the key problem that the conveying performance of an embolism agent and the embolism strength are difficult to coordinate is solved, the preparation process is mild in condition, safe and controllable, and wide application prospects are achieved in interventional embolism treatment.

The invention relates to an embolic agent infusion control method, system and equipment based on reinforcement learning and a medium. The method comprises the following steps: constructing an intraoperative blood vessel dynamic topology model in real time, and fusing multi-modal sensing data to generate a standardized state vector; adaptively deciding a pressure adjustment and target branch selection instruction by using a reinforcement learning agent according to the vascular morphological change; curvature compensation flow calculation is carried out in combination with geometric characteristics of the blood vessel, and a precise injection control signal is generated; and monitoring the embolism risk of the non-target area in real time based on the diffusion state of the embolism agent and feeding back an optimization decision strategy. According to the method, the problem of non-targeted embolism caused by static parameter setting and open-loop control in the traditional embolism is solved, the intraoperative dynamic sensing of vascular variation and precise embolism agent delivery of closed-loop feedback regulation are realized, and the clinical operation risk is remarkably reduced.

The present application relates to a kind of anisotropic hydrogel material and its preparation method;Formulate the solution containing monomer, crosslinking agent, photoinitiator, polyamino acid ester with alpha-helix structure and solvent;By shear force or magnetic field effect makes polyamino acid ester molecule in solution orientation form nematic liquid crystal, obtain the solution with orientation structure;After photoinitiation polymerization, obtain polyamino acid ester composite gel;Composite gel is hydrolyzed in hydrogen bromide acetic acid solution, and polyamino acid ester with alpha-helix structure is hydrolyzed into polyamino acid with alpha-helix structure, obtain the anisotropic hydrogel with pH sensitivity.The anisotropic hydrogel material is composed of polyamino acid with alpha-helix structure and ordinary hydrogel matrix.Polyamino acid embedded in hydrogel matrix forms highly oriented liquid crystal structure.The anisotropic hydrogel has higher anisotropy index, generally greater than 2.The anisotropic hydrogel material prepared by the present application is applied to embolization agent.

The invention provides a temperature response type magnetic emulsion embolization agent containing triptolide as well as a preparation method and application of the temperature response type magnetic emulsion embolization agent, and belongs to the technical field of biological medicines. The triptolide temperature response type magnetic emulsion embolization agent comprises triptolide, a temperature-sensitive polymer, iodized oil and magnetic nanoparticles, and the temperature-sensitive polymer can be subjected to phase change at 32 DEG C or above to be gelated. The triptolide temperature response type magnetic emulsion embolism agent provided by the invention can continuously release triptolide and has excellent mechanical properties to realize long-acting tumor vascular embolism, and the magnetic nanoparticles can effectively exert magnetocaloric properties to realize an anti-tumor effect; the iodinated oil has X-ray opaqueness and can be visualized in an embolism operation, the safety in the using process is improved, and then the triple synergistic anti-tumor effect of embolism, chemotherapy and magnetic hyperthermia is achieved.